Skip to content

Talk Bio

Actionable Insights Powered by AI

Subscribe
  • Privacy policy
  • Subscribe
  • Home
  • 2024
  • May
  • 21

May 21, 2024

  • ENTITY
  • Functional Concept
  • GPE

AstraZeneca’s Billion-Dollar Bet: Accelerating Biopharma Innovation in China

1 year ago talkbio0Tagged AstraZeneca, Biopharma, China sales, Clinical Trials, Collaboration, development aspects, Drug Industry, Health care facility, innovation, Investments, partnerships, research

AstraZeneca, China sales, biopharma innovation, investment, research and development, healthcare market, pharmaceutical industry, clinical trials, partnerships, collaborations.

Read More
  • Biomedical Occupation or Discipline
  • ENTITY
  • Geographic Area

AstraZeneca Invests $1.5 Billion in Singapore for Comprehensive Antibody-Drug Conjugate Manufacturing

1 year ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, Biotechnology, Cancer Therapeutic Procedure, end-to-end, Investments, Manufacture, production, Singapore

AstraZeneca, Singapore, antibody-drug conjugate (ADC), manufacturing, investment, biotechnology, pharmaceuticals, end-to-end production, cancer treatment.

Read More
  • Biomedical Occupation or Discipline
  • DATE
  • ENTITY

Rapport, a J&J Neuroscience Spinout, Prepares for Summer IPO as the First Biotech of the Season

1 year ago talkbio0Tagged IPO, J&J, Neuroscience discipline, plans, Rapport, Summer, Third Rock

Rapport, IPO, J&J, neuroscience, biotech, summer plans, Third Rock.

Read More
  • Biologically Active Substance
  • Biomedical Occupation or Discipline
  • ENTITY

FDA Greenlights Biocon Biologics and Biogen’s Eylea Biosimilars: A New Era in Ophthalmology

1 year ago talkbio0Tagged Biocon, Biogen, Biological Factors, Biosimilars, Eylea, Ophthalmology specialty, regulatory approval, United States Food and Drug Administration

FDA, Eylea, biosimilars, Biocon Biologics, Biogen, ophthalmology, aflibercept, regulatory approval

Read More
  • Biologic Function
  • Biomedical Occupation or Discipline
  • Disease or Syndrome

Revolutionizing Drug Discovery: Sanofi, OpenAI, and Formation Bio Join Forces

1 year ago talkbio0Tagged Anabolism, Artificial Intelligence, Bio, Drug Development, Drug Discovery, healthcare innovation, OpenAI, Partnership, sanofi

Sanofi, OpenAI, Formation Bio, AI, drug development, partnership, drug discovery, pharmaceuticals, artificial intelligence, healthcare innovation.

Read More
  • Biomedical Occupation or Discipline
  • ENTITY
  • Geographic Area

AstraZeneca’s Ambitious Vision: Pursuing $80 Billion in Revenue and 20 New Drugs by 2030

1 year ago talkbio0Tagged AstraZeneca, Biotechnology, Drug Development, Drug Industry, expansion, growth strategy, healthcare innovation, Market

AstraZeneca, revenue target, new drugs, 2030, growth strategy, pharmaceutical industry, healthcare innovation, biotechnology, drug development, market expansion.

Read More
  • Disease or Syndrome
  • ENTITY
  • Health Care Related Organization

Exscientia, AI Biotech Firm, Announces Workforce Reduction Amidst Pipeline Changes and CEO Departure

1 year ago talkbio0Tagged AI, Artificial Intelligence, CEO, Drug Discovery, Drug Industry, Exscientia, firing, restructuring

Exscientia, AI biotech, workforce reduction, pipeline cut, CEO firing, restructuring, pharmaceutical industry, drug discovery

Read More
  • Disease or Syndrome
  • ENTITY
  • Functional Concept

GSK’s Novel Long-Acting Asthma Treatment Shows Promising Results in Phase 3 Trials

1 year ago talkbio0Tagged Asthma, Clinical Trials, Effectiveness, long-acting, Phase 3 studies, Safety, SmithKline Beecham

GSK, asthma treatment, Phase 3 studies, long-acting, clinical trials, efficacy, safety, respiratory disease

Read More
  • Biomedical Occupation or Discipline
  • DATE
  • ENTITY

AstraZeneca Targets $80 Billion in Revenue by 2030: A Rapid Growth Trajectory

1 year ago talkbio0Tagged 2030, AstraZeneca, Drug Development, Drug Industry, growth trajectory, healthcare solutions

AstraZeneca, revenue target, 2030, growth trajectory, pharmaceutical industry, drug development, healthcare solutions.

Read More
  • Biomedical Occupation or Discipline
  • Disease or Syndrome
  • ENTITY

AltruBio Secures $225M for Midphase Ulcerative Colitis Program Following Checkpoint Drug Modification

1 year ago talkbio0Tagged AltruBio, Biotechnology, checkpoint drug, Drug Development, healthcare innovation, midphase, midphase program, Ulcerative Colitis

AltruBio, checkpoint drug, ulcerative colitis, $225M funding, midphase program, biotechnology, drug development, healthcare innovation.

Read More

Posts pagination

1 2 Next

Organizations

Agencies amgen AstraZeneca boehringer ingelheim Centers for Disease Control and Prevention (U.S.) Congress (U.S. Legislature) court Drug Industry European Medicines Agency genentech Government Health care facility Johnson and Johnson Moderna Novavax Partnership Pfizer Pharmacy Benefit Manager Pharmacy facility Roche (company) sandoz sanofi squibb United States Federal Trade Commission United States Food and Drug Administration World Health Organization

Concepts & Ideas

Accelerated Accelerated Approval Access accessibility Approved aspects of adverse effects asset Bankruptcy Benefit Capacity Capital Changing Chinese Language Clearance Clinical Data Combined commercial Complete Compound Contract agreement Cost Effectiveness development aspects Discontinuation (procedure) Diversity Dosage drug price Drug Shortage earnings Economic Inflation Effectiveness Efficiency Expectations Failed Failure (biologic function) Financial cost Financial savings financing characteristics Funding Generalized Health Identifier Improvement Increased Infrequent Legal Legal patent Long-term Moderate (severity modifier) New Drug Application Overall Survival Paroxysmal perioperative Phase 2 Phase 3 Prices Pricing Programs - Publication Format Progression-Free Survival Projections and Predictions Recommendation regulatory Review [Publication Type] rights Risk Series Statistical Significance Study on Hold subcutaneous Submission Symptoms aspect Toxicity aspects trends qualifier Variant Weekly

Procedures

Advice Cancer Therapeutic Procedure Cell Therapy Clinical Research Clinical Trials Combined Modality Therapy Confirmatory Trial Detection Drug Discovery Evaluation Gene Modification gene therapy HIV prevention Immunotherapy Injection of therapeutic agent Medical Research activity patient safety Pharmaceutical Services Pharmacotherapy Phase 2 Clinical Trials Phase 3 Clinical Trials Precision Medicine Prescription procedure Reparative closure research Telemedicine Vaccination

Occupations

Artificial Intelligence biology (field) Biotechnology Drug Development Genetic Medicine Global Health Immunology medical technology Neurology speciality Neuroscience discipline public health medicine (field) Science Science of genetics Technology

Disorders

Achondroplasia Acute onset pain Adverse event Amyotrophic Lateral Sclerosis Angioedemas, Hereditary Aortic Valve Insufficiency Asthma Attention deficit hyperactivity disorder Autoimmune Diseases Brain Neoplasms Burning Mouth Syndrome Cardiomyopathies Cardiovascular Diseases Chronic Kidney Diseases Chronic Obstructive Airway Disease Colorectal Carcinoma COVID19 (disease) Dental Plaque Dermatitis, Atopic Diabetes Diabetes Mellitus, Non-Insulin-Dependent Disease Progression Eczema Epilepsy Esophageal Neoplasms Fibrosis Heart failure Hematologic Neoplasms Hemophilia A Hemophilia B Hereditary Diseases Hypoparathyroidism IGA Glomerulonephritis Infantile Severe Myoclonic Epilepsy Inflammation Inflammatory Bowel Diseases Inflammatory disorder Kidney Diseases leukemia Liver and Intrahepatic Biliary Tract Carcinoma Liver diseases Lung diseases Lupus Nephritis Lymphoma, Follicular Malignant neoplasm of breast Malignant neoplasm of endometrium Malignant neoplasm of lung Malignant neoplasm of prostate Malignant neoplasm of stomach Malignant neoplasm of urinary bladder Malignant Neoplasms Malignant tumor of cervix melanoma Mental Depression Mental deterioration Metabolic Diseases Multiple Acyl Coenzyme A Dehydrogenase Deficiency Multiple Myeloma Multiple Sclerosis Muscular Dystrophy Muscular Dystrophy, Duchenne Nance-Horan syndrome Narcolepsy Neoplasms Nerve Degeneration nervous system disorder Neurodegenerative Disorders Non-Small Cell Lung Carcinoma Nonalcoholic Steatohepatitis Obesity Paroxysmal nocturnal hemoglobinuria Post-Traumatic Stress Disorder Primary Biliary Cholangitis Psoriasis Pulmonary arterial hypertension Pulmonary Hypertension Reduced Schizophrenia Seizures Severe (severity modifier) Small cell carcinoma of lung Solid Neoplasm Spinal Muscular Atrophy Ulcerative Colitis Urinary tract infection Weight Loss

Objects

Arrowhead Facility (object) Investments Labels (device)

Chemicals & Drugs

Agonist agonists Antibiotics Antibodies Antibodies, Bispecific Antibody-Drug Conjugates Antineoplastic Agents Biological Factors Biosimilars BTK Inhibitor Cancer Vaccines Caplyta Clesrovimab Clustered Regularly Interspaced Short Palindromic Repeats Donanemab Dosage Forms Dupixent durvalumab Enhertu Epidermal Growth Factor Receptor Glucagon-Like Peptide-1 Receptor Glucagon-Like Peptide 1 Humira Imfinzi Immunologic Adjuvants Immunostimulating conjugate (antigen) Inhibitor inhibitors Insulin Jemperli Keytruda Lenacapavir Lumateperone Microbicides Midomafetamine Monoclonal Antibodies Mounjaro Nitroglycerin/Sodium Citrate/Ethanol Solution obinutuzumab Ocaliva Opdivo Ozempic patritumab Pediatric brand name pembrolizumab Primary Endpoint Radiopharmaceuticals RNA RNA, Messenger RNA, Small Interfering Rybrevant semaglutide Stelara Tagrisso Tecentriq therapeutic autologous dendritic cells tirzepatide Tremfya Trodelvy Vaccines Wegovy Weight-Loss Agents Zantac

Activities & Behaviors

Acquisition (action) Administration occupational activities Advisory Committees Agreement authorization Automation business career CEO Collaboration competition Continuance of life Drug Approval Industry Leadership Machine Learning Manufacture Mediation Medicare National Security Optimization production Rating (action) Rejection (Psychology) Relations Sales - occupational activity Settlement and Resettlement Success Withdraw (activity)

Geographic Areas

California China Japan Market North Carolina Singapore United States

Phenomena

Emergency Situation Motor function (observable entity) Safety

Living Beings

Adult Child Consumer European (ethnic group) HIV Ira (eukaryote) manager Partner in relationship Pet Animal Plants Plant seeds Respiratory syncytial virus

Anatomy

Cardiovascular system Carvykti Cells Liver Neurosecretory Systems T-Lymphocyte

Physiology

Biological Markers cellular targeting Cessation of life Decision Gene Expression Growth Hearing Immune response Menopause mental health Mutation Practice Experience Response process RNA Interference

Genes & Molecular Sequences

CSHL1 gene K-ras Oncogene PDCD1 gene PREP gene TIGIT gene TYK2 gene
Copyright © TalkBio 2024 Proudly powered by WordPress | Theme: ogma-blog by Mystery Themes.
  • Privacy policy
  • Subscribe